Please login to the form below

Not currently logged in
Email:
Password:

117,000 hepatitis C patients receive Sovaldi so far

Breakthrough drug has made $8.5bn for Gilead this year
Gilead Sovaldi

Gilead Sciences' blockbuster hepatitis C drug Sovaldi has been used in around 117,000 people since its launch at the end of last year, said the company in its latest financial report.

Sovaldi (sofosbuvir), which allows patients to be treated without the need for weekly injectable interferon, has been the most lucrative pharma launch of all time, and has recorded revenues of $8.5bn in the first nine months of 2014 and $2.8bn for the three-month period between July and September.

This uptake has been despite criticism from some corners of the US unhappy with the drug's high price – around $84,000 per standard course of treatment – with senators asking Gilead to justify the cost of Sovaldi.

Around 70% of US state Medicaid programmes have implemented controls on Sovaldi prescribing - including prior authorisation requirements based on disease severity  - amid warnings that some healthcare systems may buckle under the strain of providing the drug.

Nevertheless the massive revenues so far put Sovaldi way ahead of Gilead's second biggest selling medicine Atripla, a combination of several HIV treatments. The drug made $2.5bn for the first nine months of the year and just under $900m over the third quarter, both slightly down on the same periods last year.

The huge boost from Sovaldi saw Gilead's total revenues rocket from $8.1bn for the first nine months of 2013 to $17.5bn for the same period in 2014.

Net income was also up, with Gilead taking $8.6bn for the first nine months of 2014 compared to $2.3bn a year previous.

Company revenues should continue to grow with the upcoming launch of Harvoni, a combination of Sovaldi and other hepatitis C treatment ledipasvir.

The drug was recommended for use in Europe at the end of September and approved in the US a couple of weeks later and expectations are high, with trial data demonstrating the drug can cure as many as 90% of patients within just eight weeks.

Article by
Thomas Meek

29th October 2014

From: Research, Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...